NRAS and neoplasm: Additionally, the combination of belvarafenib, a type II RAF inhibitor, with cobimetinib has been demonstrated to delay acquired resistance mediated by ARAF mutations in NRAS-mutant tumor cells preclinically, and in the clinic, this combination exhibited acceptable tolerability and encouraging efficacy in patients with NRAS-mutant melanoma (44, 45).